CCL5 and neoplasm: AdKi67-DsRed, AdKi67-CCL5, AdKi67-C2 or AdKi67-C3 was administrated by intra-tumor injection and B7H3-CAR-T cells were infused through tail-vein on the next day of last OAV administration on combination therapy groups.